Company Product Description Indication Status
Bellerophon Therapeutics Inc., of Warren, N.J. Inopulse Pulsatile nitric oxide delivery system Pulmonary hypertension associated with pulmonary fibrosis Finalized, in consultation with FDA, key elements of planned pivotal phase III trial, including use of moderate to vigorous physical activity as the primary endpoint for approval, the population of PF subjects at risk of PH, as well as the dose of iNO45 (45 mcg/kg IBW/hr)
Cadent Therapeutics Inc., of Cambridge, Mass. CAD-9303 Positive allosteric modulator of NMDA Schizophrenia FDA cleared the IND for a phase I trial in schizophrenia patients and healthy volunteers
Daré Biosciences Inc., of San Diego DARE-BV1  Thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% Bacterial vaginosis FDA granted fast track designation
Freeline Therapeutics Ltd., of London FLT-190 Liver-directed AAV gene therapy Fabry disease European Commission granted orphan designation

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments